Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Multi-peptide Vaccine + XS15 in CLL
NCT04688385Phase 1Completed
- Sponsor
- University Hospital Tübingen
- Start
- Dec 2020
- Primary completion
- Oct 2024
- Modality
- Antisense DNA, Vaccines & Immunotherapeutics, Modified Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PGV-001 and XS15 in chronic lymphocytic leukemia (CLL), sponsored by University Hospital Tübingen. Primary endpoints: Induction of a T-cell response after vaccination and Safety and toxicity. Started Dec 2020; status: completed.
02
Drugs
PGV-001XS15
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT04688385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04688385.